Michael Graham Joins Enzymedica as Vice President of Operations
As Vice President of Operations, Graham will play a key role in optimizing Enzymedica's supply chain, manufacturing processes and overall operational efficiency. His extensive experience positions him well to contribute to Enzymedica's commitment to excellence and innovation.
"We are excited to welcome
Graham's background includes a successful tenure at Teva Pharmaceuticals, where he played a vital role in streamlining operations and implementing strategic initiatives. His strong leadership skills and results-driven approach make him a valuable addition to the Enzymedica team.
"I am honored to join Enzymedica and contribute to the continued success of a company known for its commitment to quality and innovation in the supplement industry," says Graham. "I look forward to collaborating with the talented team at Enzymedica to enhance operational excellence and drive growth."
Enzymedica has been at the forefront of providing supplements that support digestive health, immunity and overall wellness. With Graham as Vice President of Operations, the company is well-positioned to strengthen its operational capabilities, ensuring the continued delivery of high-quality products to its customers.
About Enzymedica:
Enzymedica is a trusted leader in the field of digestive health, committed to providing natural, effective solutions for various digestive concerns. With a focus on innovation and science-backed formulations, Enzymedica offers consumers a wide range of products that promote optimal digestive wellness.
For media inquiries, please contact:
(484) 241-6926
372439@email4pr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/michael-graham-joins-enzymedica-as-vice-president-of-operations-302053473.html
SOURCE Enzymedica
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southern Company's experienced storm response teams, advanced storm intelligence technologies drive power restoration following Hurricane Isaias
- Korean Cultural Center New York Presents "Tchah Sup Kim: The Key to a New World," Featuring an Artwork on Loan from MoMA
- Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share